Skip to main content
Figure 2 | Journal of Hematology & Oncology

Figure 2

From: A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors

Figure 2

A 67-year old female patient diagnosed with MBC who had experienced treatment failure after 2 chemotheraphy and 2 hormonal regimens, but did not receive trastuzumab. She had confirmed PR at the 1500 mg BID dose level of AST1306, but withdrew from the study after 9 months due to continuous grade 2 diarrhea. A) CT imaging of the metastatic lesion prior to starting therapy, and B) shows the response to AST1306 two cycles after starting therapy. C and D shows continued response three and ten cycles after starting therapy.

Back to article page